Loading…

The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases

Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased product...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-03, Vol.23 (7), p.3439
Main Authors: Steenbeke, Mieke, Speeckaert, Reinhart, Desmedt, Stéphanie, Glorieux, Griet, Delanghe, Joris R, Speeckaert, Marijn M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c478t-6f672b4c7942286762bd2b9240b963e6ff824ef2e7edbfa41b7fcbb21c053c753
cites cdi_FETCH-LOGICAL-c478t-6f672b4c7942286762bd2b9240b963e6ff824ef2e7edbfa41b7fcbb21c053c753
container_end_page
container_issue 7
container_start_page 3439
container_title International journal of molecular sciences
container_volume 23
creator Steenbeke, Mieke
Speeckaert, Reinhart
Desmedt, Stéphanie
Glorieux, Griet
Delanghe, Joris R
Speeckaert, Marijn M
description Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.
doi_str_mv 10.3390/ijms23073439
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4a25514526d64fdc9927fbfa3798991f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4a25514526d64fdc9927fbfa3798991f</doaj_id><sourcerecordid>2649057453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-6f672b4c7942286762bd2b9240b963e6ff824ef2e7edbfa41b7fcbb21c053c753</originalsourceid><addsrcrecordid>eNpdkctPVDEUh2-MRhDduTZN3LhwoLfP240JQYSJJBrEuGz6OIVO7twO7b0k899bZoAMrE4f3_ly2l_TfGzxIaUKH8XFshCKJWVUvWr2W0bIDGMhX--s95p3pSwwJpRw9bbZo5zhTiqx3_y7ugF0mXpAKaBjf2cGBx6d9WtnxpgGdDp49DsnP7mxIFM381r_pH6yteUSHKzGlFEc0M_oB1ij77GAKVDeN2-C6Qt8eKgHzd8fp1cn57OLX2fzk-OLmWOyG2ciCEksc1LVUTshBbGeWEUYtkpQECF0hEEgIMHbYFhrZXDWktZhTp3k9KCZb70-mYVe5bg0ea2TiXpzkPK1NnmMrgfNDOG8ZZwIL1jwTikiQ5VSqTql2lBd37au1WSX4B0MYzb9M-nzmyHe6Ot0p2t7122G-fIgyOl2gjLqZSwO-t4MkKaiiWCKd4oLUdHPL9BFmvJQv2pDYS4Zp5X6uqVcTqVkCE_DtFjfp69306_4p90HPMGPcdP_ZwqqRg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649057453</pqid></control><display><type>article</type><title>The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Steenbeke, Mieke ; Speeckaert, Reinhart ; Desmedt, Stéphanie ; Glorieux, Griet ; Delanghe, Joris R ; Speeckaert, Marijn M</creator><creatorcontrib>Steenbeke, Mieke ; Speeckaert, Reinhart ; Desmedt, Stéphanie ; Glorieux, Griet ; Delanghe, Joris R ; Speeckaert, Marijn M</creatorcontrib><description>Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms23073439</identifier><identifier>PMID: 35408796</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>advanced glycation end products (AGEs) ; Advanced glycosylation end products ; Age ; Binding sites ; Biomarkers ; Body mass index ; Cardiovascular Diseases ; Chromatography ; Chronic illnesses ; chronic kidney disease (CKD) ; Cytokines ; Diabetes ; Glycation End Products, Advanced ; Glycosylation ; Humans ; Inflammation ; Kidney diseases ; Kinases ; Ligands ; NF-κB protein ; Oxidative stress ; Proteins ; Receptor for Advanced Glycation End Products ; Renal Insufficiency, Chronic ; Review ; Risk analysis ; Risk factors ; Skin ; soluble receptor for AGEs (sRAGE) ; Toxicity ; Tumor necrosis factor-TNF ; Uremia</subject><ispartof>International journal of molecular sciences, 2022-03, Vol.23 (7), p.3439</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-6f672b4c7942286762bd2b9240b963e6ff824ef2e7edbfa41b7fcbb21c053c753</citedby><cites>FETCH-LOGICAL-c478t-6f672b4c7942286762bd2b9240b963e6ff824ef2e7edbfa41b7fcbb21c053c753</cites><orcidid>0000-0003-2731-7545 ; 0000-0002-6846-6558 ; 0000-0002-5702-6792 ; 0000-0001-9183-4390 ; 0000-0002-7641-4707</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2649057453/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2649057453?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35408796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steenbeke, Mieke</creatorcontrib><creatorcontrib>Speeckaert, Reinhart</creatorcontrib><creatorcontrib>Desmedt, Stéphanie</creatorcontrib><creatorcontrib>Glorieux, Griet</creatorcontrib><creatorcontrib>Delanghe, Joris R</creatorcontrib><creatorcontrib>Speeckaert, Marijn M</creatorcontrib><title>The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.</description><subject>advanced glycation end products (AGEs)</subject><subject>Advanced glycosylation end products</subject><subject>Age</subject><subject>Binding sites</subject><subject>Biomarkers</subject><subject>Body mass index</subject><subject>Cardiovascular Diseases</subject><subject>Chromatography</subject><subject>Chronic illnesses</subject><subject>chronic kidney disease (CKD)</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Glycation End Products, Advanced</subject><subject>Glycosylation</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Kidney diseases</subject><subject>Kinases</subject><subject>Ligands</subject><subject>NF-κB protein</subject><subject>Oxidative stress</subject><subject>Proteins</subject><subject>Receptor for Advanced Glycation End Products</subject><subject>Renal Insufficiency, Chronic</subject><subject>Review</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Skin</subject><subject>soluble receptor for AGEs (sRAGE)</subject><subject>Toxicity</subject><subject>Tumor necrosis factor-TNF</subject><subject>Uremia</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkctPVDEUh2-MRhDduTZN3LhwoLfP240JQYSJJBrEuGz6OIVO7twO7b0k899bZoAMrE4f3_ly2l_TfGzxIaUKH8XFshCKJWVUvWr2W0bIDGMhX--s95p3pSwwJpRw9bbZo5zhTiqx3_y7ugF0mXpAKaBjf2cGBx6d9WtnxpgGdDp49DsnP7mxIFM381r_pH6yteUSHKzGlFEc0M_oB1ij77GAKVDeN2-C6Qt8eKgHzd8fp1cn57OLX2fzk-OLmWOyG2ciCEksc1LVUTshBbGeWEUYtkpQECF0hEEgIMHbYFhrZXDWktZhTp3k9KCZb70-mYVe5bg0ea2TiXpzkPK1NnmMrgfNDOG8ZZwIL1jwTikiQ5VSqTql2lBd37au1WSX4B0MYzb9M-nzmyHe6Ot0p2t7122G-fIgyOl2gjLqZSwO-t4MkKaiiWCKd4oLUdHPL9BFmvJQv2pDYS4Zp5X6uqVcTqVkCE_DtFjfp69306_4p90HPMGPcdP_ZwqqRg</recordid><startdate>20220322</startdate><enddate>20220322</enddate><creator>Steenbeke, Mieke</creator><creator>Speeckaert, Reinhart</creator><creator>Desmedt, Stéphanie</creator><creator>Glorieux, Griet</creator><creator>Delanghe, Joris R</creator><creator>Speeckaert, Marijn M</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2731-7545</orcidid><orcidid>https://orcid.org/0000-0002-6846-6558</orcidid><orcidid>https://orcid.org/0000-0002-5702-6792</orcidid><orcidid>https://orcid.org/0000-0001-9183-4390</orcidid><orcidid>https://orcid.org/0000-0002-7641-4707</orcidid></search><sort><creationdate>20220322</creationdate><title>The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases</title><author>Steenbeke, Mieke ; Speeckaert, Reinhart ; Desmedt, Stéphanie ; Glorieux, Griet ; Delanghe, Joris R ; Speeckaert, Marijn M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-6f672b4c7942286762bd2b9240b963e6ff824ef2e7edbfa41b7fcbb21c053c753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>advanced glycation end products (AGEs)</topic><topic>Advanced glycosylation end products</topic><topic>Age</topic><topic>Binding sites</topic><topic>Biomarkers</topic><topic>Body mass index</topic><topic>Cardiovascular Diseases</topic><topic>Chromatography</topic><topic>Chronic illnesses</topic><topic>chronic kidney disease (CKD)</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Glycation End Products, Advanced</topic><topic>Glycosylation</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Kidney diseases</topic><topic>Kinases</topic><topic>Ligands</topic><topic>NF-κB protein</topic><topic>Oxidative stress</topic><topic>Proteins</topic><topic>Receptor for Advanced Glycation End Products</topic><topic>Renal Insufficiency, Chronic</topic><topic>Review</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Skin</topic><topic>soluble receptor for AGEs (sRAGE)</topic><topic>Toxicity</topic><topic>Tumor necrosis factor-TNF</topic><topic>Uremia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steenbeke, Mieke</creatorcontrib><creatorcontrib>Speeckaert, Reinhart</creatorcontrib><creatorcontrib>Desmedt, Stéphanie</creatorcontrib><creatorcontrib>Glorieux, Griet</creatorcontrib><creatorcontrib>Delanghe, Joris R</creatorcontrib><creatorcontrib>Speeckaert, Marijn M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steenbeke, Mieke</au><au>Speeckaert, Reinhart</au><au>Desmedt, Stéphanie</au><au>Glorieux, Griet</au><au>Delanghe, Joris R</au><au>Speeckaert, Marijn M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2022-03-22</date><risdate>2022</risdate><volume>23</volume><issue>7</issue><spage>3439</spage><pages>3439-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35408796</pmid><doi>10.3390/ijms23073439</doi><orcidid>https://orcid.org/0000-0003-2731-7545</orcidid><orcidid>https://orcid.org/0000-0002-6846-6558</orcidid><orcidid>https://orcid.org/0000-0002-5702-6792</orcidid><orcidid>https://orcid.org/0000-0001-9183-4390</orcidid><orcidid>https://orcid.org/0000-0002-7641-4707</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2022-03, Vol.23 (7), p.3439
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4a25514526d64fdc9927fbfa3798991f
source Publicly Available Content Database; PubMed Central
subjects advanced glycation end products (AGEs)
Advanced glycosylation end products
Age
Binding sites
Biomarkers
Body mass index
Cardiovascular Diseases
Chromatography
Chronic illnesses
chronic kidney disease (CKD)
Cytokines
Diabetes
Glycation End Products, Advanced
Glycosylation
Humans
Inflammation
Kidney diseases
Kinases
Ligands
NF-κB protein
Oxidative stress
Proteins
Receptor for Advanced Glycation End Products
Renal Insufficiency, Chronic
Review
Risk analysis
Risk factors
Skin
soluble receptor for AGEs (sRAGE)
Toxicity
Tumor necrosis factor-TNF
Uremia
title The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A20%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Advanced%20Glycation%20End%20Products%20and%20Its%20Soluble%20Receptor%20in%20Kidney%20Diseases&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Steenbeke,%20Mieke&rft.date=2022-03-22&rft.volume=23&rft.issue=7&rft.spage=3439&rft.pages=3439-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms23073439&rft_dat=%3Cproquest_doaj_%3E2649057453%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-6f672b4c7942286762bd2b9240b963e6ff824ef2e7edbfa41b7fcbb21c053c753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2649057453&rft_id=info:pmid/35408796&rfr_iscdi=true